Bosch adds additional pharma expertise in North America — Part 2

| October 26, 2016

article image
As part of Bosch’s ongoing development of our North American sales staff, two positions have been filled to bring regional expertise to our customers in aseptic fill/finish.

Spotlight

Avara Pharmaceutical Services

Home Avara Pharmaceutical Services is a state of the art Contract Manufacturing Organization. We focus our efforts on Quality, Compliance, Customer Service, and delivering on time and in-full. We have a senior leadership that have managed manufacturing infrastructures worldwide. Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. Our team is fully aware of customers’ expectations. Therefore, we built a CDMO that provides exceptional service and a world-class experience by delivering on our commitments. These commitments include delivering to scope, schedule, meeting regulatory requirements and quality standards, all at an agreed and fair price.

OTHER ARTICLES

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 11, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | February 11, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | February 11, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

Roche Prepares to Launch COVID-19 Antibody Test System

Article | February 11, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Spotlight

Avara Pharmaceutical Services

Home Avara Pharmaceutical Services is a state of the art Contract Manufacturing Organization. We focus our efforts on Quality, Compliance, Customer Service, and delivering on time and in-full. We have a senior leadership that have managed manufacturing infrastructures worldwide. Avara Pharmaceutical Services was founded by a team of industry veterans who, through personal experience, understand both sides of the contract manufacturing market. Our team is fully aware of customers’ expectations. Therefore, we built a CDMO that provides exceptional service and a world-class experience by delivering on our commitments. These commitments include delivering to scope, schedule, meeting regulatory requirements and quality standards, all at an agreed and fair price.

Events